Many sources from the GPU industry indicated last month that neither Advanced Micro Devices, Inc. (NYSE:AMD), nor Nvidia Corp. plan to make major GPU introductions at least till late in 2014, or maybe even early 2015. Advanced Micro Devices, Inc. (NYSE:AMD) stock performance was -5.19% in last session and finished the day at $3.65. Traded volume was 34.43million shares in the last session and the average volume of the stock remained 23.82million shares. The beta of the stock remained 2.58. Advanced Micro Devices, Inc. (NYSE:AMD) insider ownership is 0.20%.

Sprint Corporation (NYSE:S), the communications company, has started “hardening” its sites so they can withstand weather varability. They’ve lessened their own emissions, and required that their suppliers do likewise, said Amy Hargroves, the company’s sustainability director. Sprint Corporation (NYSE:S) dropped-6.25 percent to $8.25 Friday on volume of 20.44million shares. The intra-day range of the stock was $8.15 to $8.77. Sprint Corporation (NYSE:S) has a market capitalization of $32.47billion.

Yingli Green Energy Holding Company Limited (ADR) (NYSE:YGE), the largest vertically integrated photovoltaic (PV) module manufacturer in the world, known as “Yingli Solar,” today announced the commencement of construction of its two ground-mounted PV plants in Hebei Province. Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)’s stock on Apr 11, 2014 reported a decrease of -6.51% to the closing price of $3.88. Its fifty two weeks range is $1.90-$8.77. The total market capitalization recorded $607.55million. The overall volume in the last trading session was 5.11million shares. In its share capital, YGE has 156.59million outstanding shares.

Celldex Therapeutics Inc. (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. On Friday, shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) dropped -10.24% to close the day at $14.02. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as -41.14%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly revenue growth is -42.52%.